Search

Search Constraints

You searched for: Author/Creator Verdonschot, Job A.J.

Search Results

1. A global longitudinal strain cut‐off value to predict adverse outcomes in individuals with a normal ejection fraction. (17th July 2021)

2. Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. (9th December 2021)

3. Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. (November 2020)

4. Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients. Issue 12 (22nd September 2020)

5. Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant. (11th May 2022)

6. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial. (6th September 2022)

7. Implications of Genetic Testing in Dilated Cardiomyopathy. (October 2020)

8. Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. (4th February 2022)

9. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. (5th March 2022)

10. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controlled clinical trial. (7th January 2021)